Oxidation； drugs； drugs； treatment； drugs； treatment； treatment； and use of polychlorinated dioxide； and polychlorinated dioxide； and polychlorinated dioxide； drugs； and polychlorinated and other diseases
The present invention relates to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-l,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide and polymorphic forms and pharmaceutical compositions thereof for use in the treatment of cancer in combination with immunotherapy, for use in the treatment of conditions associated with oxidative stree caused by mitochondrial dysfunction and for use in the treatment of seizure disorders.N-((4AS, 6AR, 6BS, 8AR, 12AS, 14AR, 14BS)-11-CIANO-2, 2, 6A, 6B, 9, 9, 12A-HEPTAMETIL-10,14-DIOXO-1, 2, 3, 4, 4A, 5, 6, 6A, 6B, 7, 8, 8A, 9, 10, 12A, 14, 14A, 14B-OCTADECAHIDROPICEN-4A-IL)-2,2-DIFLUORO PROPANAMIDA； FORMAS POLIMÓRFICAS； COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE； Y SU USO EN EL TRATAMIENTO DE INFLAMACIÓN, ESTRÉS OXIDATIVO, HIPERPROLIFERACIÓN CELULAR, ENTRE OTROS.
